单细胞免疫生态系统区分真性复发与新发HBV相关肝细胞癌复发
该研究对20例复发性肝细胞癌患者的34份样本行5'端及VDJ单细胞RNA测序,并通过全外显子测序区分真性复发与新发复发,发现两者肿瘤免疫微环境不同,真性复发以KLRB1+CD8+记忆表型T细胞增多为特征,新发复发以细胞毒性及耗竭CD8+ T细胞富集为特征,新辅助抗PD-1治疗的2期试验中新发复发患者应答更多。
要点
- 真性复发肿瘤免疫微环境以KLRB1+CD8+记忆表型且低细胞毒性T细胞增多为特征。
- 新发复发肿瘤免疫微环境中细胞毒性和耗竭CD8+ T细胞富集。
- 新辅助抗PD-1免疫治疗2期试验显示新发复发患者应答更多。
核心结论
- 真性与新发肝细胞癌复发发生早,肿瘤免疫微环境不同,可能需要不同的免疫治疗策略。
- 该研究为基于肝细胞癌复发类型和特定肿瘤免疫微环境的免疫治疗提供了基因组诊断和免疫图谱来源。
研究设计与样本
- 对20例复发性肝细胞癌患者的34份样本行5'端及VDJ单细胞RNA测序。
- 在两个验证队列样本中行批量RNA测序、流式细胞术、多重免疫荧光和体外功能分析。
- 利用全外显子测序分析配对原发与复发肝细胞癌样本的突变谱和进化轨迹以区分新发与真性复发。
主要发现
- 部分复发在临床诊断之前即已发生。
- 真性复发肝细胞癌的肿瘤免疫微环境以KLRB1+CD8+记忆表型且低细胞毒性T细胞丰度增加为特征。
- 新发复发肝细胞癌的肿瘤免疫微环境中细胞毒性和耗竭CD8+ T细胞富集。
- 转录组和相互作用分析显示邻近树突状细胞的肝细胞癌细胞的GDF15表达升高,可能削弱抗原呈递并抑制真性复发灶的抗肿瘤免疫。
- 新发复发肝细胞癌的肿瘤免疫微环境中髓系细胞与T细胞交互介导T细胞耗竭和免疫抑制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Revealing the single-cell immune ecosystems in true versus de novo hepatocellular carcinoma (HCC) recurrences could help the optimal development of immunotherapies. DESIGN: We performed 5'and VDJ single-cell RNA-sequencing on 34 samples from 20 recurrent HCC patients. Bulk RNA-sequencing, flow cytometry, multiplexed immunofluorescence, and in vitro functional analyses were performed on samples from two validation cohorts. RESULTS: Analyses of mutational profiles and evolutionary trajectories in paired primary and recurrent HCC samples using whole-exome sequencing identified de novo versus true recurrences, some of which occurred before clinical diagnosis. The tumour immune microenvironment (TIME) of truly recurrent HCCs was characterised by an increased abundance in KLRB1+CD8+ T cells with memory phenotype and low cytotoxicity. In contrast, we found an enrichment in cytotoxic and exhausted CD8+ T cells in the TIME of de novo recurrent HCCs. Transcriptomic and interaction analyses showed elevated GDF15 expression on HCC cells in proximity to dendritic cells, which may have dampened antigen presentation and inhibited antitumour immunity in truly recurrent lesions. In contrast, myeloid cells' cross talk with T cells-mediated T cell exhaustion and immunosuppression in the TIME of de novo recurrent HCCs. Consistent with these findings, a phase 2 trial of neoadjuvant anti-PD-1 immunotherapy showed more responses in de novo recurrent HCC patients. CONCLUSION: True and de novo HCC recurrences occur early, have distinct TIME and may require different immunotherapy strategies. Our study provides a source for genomic diagnosis and immune profiling for guiding immunotherapy based on the type of HCC recurrence and the specific TIME.
引用
- Chen S, Huang C, Liao G, et al. Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences. Gut. 2023. PMID: 36596711. doi:10.1136/gutjnl-2022-328428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。